Northern Trust’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-923,900
| Closed | -$17.4M | – | 4361 |
|
|
2019
Q3 | $17.4M | Buy |
923,900
+142,078
| +18% | +$1.62M | ﹤0.01% | 1781 |
|
|
2019
Q2 | $9.2M | Buy |
781,822
+31,794
| +4% | +$385K | ﹤0.01% | 2206 |
|
|
2019
Q1 | $10.2M | Buy |
750,028
+48,559
| +7% | +$629K | ﹤0.01% | 2126 |
|
|
2018
Q4 | $7.19M | Sell |
701,469
-8,973
| -1% | -$115K | ﹤0.01% | 2283 |
|
|
2018
Q3 | $11.8M | Buy |
710,442
+11,086
| +2% | +$200K | ﹤0.01% | 2164 |
|
|
2018
Q2 | $11.1M | Sell |
699,356
-5,493
| -0.8% | -$83.5K | ﹤0.01% | 2208 |
|
|
2018
Q1 | $8.95M | Buy |
704,849
+2,245
| +0.3% | +$32.5K | ﹤0.01% | 2239 |
|
|
2017
Q4 | $8.04M | Sell |
702,604
-26,923
| -4% | -$301K | ﹤0.01% | 2335 |
|
|
2017
Q3 | $8.94M | Buy |
729,527
+160,236
| +28% | +$1.67M | ﹤0.01% | 2274 |
|
|
2017
Q2 | $6.52M | Buy |
569,291
+11,544
| +2% | +$213K | ﹤0.01% | 2455 |
|
|
2017
Q1 | $11.6M | Buy |
557,747
+5,259
| +1% | +$116K | ﹤0.01% | 2019 |
|
|
2016
Q4 | $11.5M | Buy |
552,488
+3,331
| +0.6% | +$86.6K | ﹤0.01% | 2017 |
|
|
2016
Q3 | $18M | Sell |
549,157
-8,057
| -1% | -$245K | 0.01% | 1670 |
|
|
2016
Q2 | $13.9M | Buy |
557,214
+289,387
| +108% | +$7.83M | ﹤0.01% | 1794 |
|
|
2016
Q1 | $6.56M | Buy |
267,827
+4,870
| +2% | +$113K | ﹤0.01% | 2248 |
|
|
2015
Q4 | $8.69M | Buy |
262,957
+7,894
| +3% | +$267K | ﹤0.01% | 2108 |
|
|
2015
Q3 | $8.36M | Buy |
255,063
+126,248
| +98% | +$5.37M | ﹤0.01% | 2117 |
|
|
2015
Q2 | $6.82M | Buy |
128,815
+15,339
| +14% | +$558K | ﹤0.01% | 2314 |
|
|
2015
Q1 | $3.27M | Buy |
113,476
+29,591
| +35% | +$812K | ﹤0.01% | 2793 |
|
|
2014
Q4 | $2.44M | Sell |
83,885
-1,748
| -2% | -$31.4K | ﹤0.01% | 2976 |
|
|
2014
Q3 | $1.09M | Buy |
85,633
+54,313
| +173% | +$821K | ﹤0.01% | 3395 |
|
|
2014
Q2 | $628K | Buy |
+31,320
| New | +$441K | ﹤0.01% | 3537 |
|
Northern Trust's ALDR Position: Q4 2019 in Review
Northern Trust sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 923,900 shares — an estimated $17.4M sold.
Northern Trust first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $18M in Q3 2016. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Northern Trust reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Northern Trust sold 923,900 Alder Biopharmaceuticals shares in Q4 2019, an estimated $17.4M.
- Northern Trust first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
- Northern Trust's Alder Biopharmaceuticals position peaked at $18M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Northern Trust's 13F filing for Q4 2019, filed 14 Feb 2020.